Batavia Biomanufacturing facility in Leiden completed

On 13 December 2024 Provast completed the development of Batavia Biosciences and Batavia Biomanufacturing in Leiden. The validation and qualification of the production process will take place in coming months. CBRE Investment Management has added the building, located directly adjacent to the A44 motorway, to their portfolio.

The facility is operational in the first half of 2025 and accommodates high-tech laboratories, cleanrooms and offices for the clinical and commercial production of viral vectors and vaccines and functions as a so-called “pandemic preparedness facility”. The building complies to EU GMP (PICs) and Biosafety Level (BSL)-2 containment standards for both genetically modified and non-genetically modified organisms.

 The building is fully electric and will achieve BREEAM Excellent certification, for example by the use of circular concrete and a recyclable aluminium façade. The nature-inclusive landscaping of the site will be completed early 2025.

Thanks to the close cooperation with the University Leiden, the municipality of Leiden and DCMR Milieudienst Rijnmond the planning permission was granted in March 2023, a record time. The project is build by De Vries en Verburg, according to the design of Paul de Ruiter Architects, and handed-over in 2024.  Involved advisors are IMd Raadgevende Ingenieurs, Ingenieursburo Linssen, DGMR, bbn adviseurs, C2N, bouAd adviesgroep, CBRE, Loyens & Loeff, CMS and NautaDutilh.